低危妊娠中指征性 vs 普遍性晚孕期超声检查:一项干预前后研究
该干预前后研究在9个地点纳入低危妊娠,比较指征性超声与36.0-37.6周普遍性超声对围产结局的影响。普遍性超声组胎儿生长或羊水异常检出率升高(7.1% vs 22.2%,P<.0001),新生儿复合不良结局风险降低83%概率(后验相对风险0.69,95%可信区间0.34-1.42),母体复合不良结局风险降低90%概率(后验相对风险0.74,95%可信区间0.49-1.15)。
要点
- 低危妊娠36.0-37.6周普遍超声使胎儿生长或羊水异常检出率从7.1%升至22.2%(P<.0001)。
- 新生儿复合不良结局后验相对风险0.69(95%可信区间0.34-1.42),风险降低概率83%。
- 母体复合不良结局后验相对风险0.74(95%可信区间0.49-1.15),风险降低概率90%。
核心结论
- 在低危妊娠中,与指征性超声检查的常规护理相比,实施36.0-37.6周普遍性晚孕期超声检查减轻了新生儿和母体复合不良结局。
研究设计与样本
- 干预前后研究,在9个地点纳入无晚孕期超声检查指征的低危妊娠。
- 干预前阶段初始超声检查时识别747人,其中568人(76.0%)在36.0-37.6周符合纳入标准;干预后阶段相应为770人和661人(85.8%)。
- 干预后阶段所有患者安排在36.0-37.6周接受超声检查;两个阶段临床医生均根据发现的异常进行干预。
- 采用贝叶斯统计,每组计算样本量600人以检测主要结局任何降低的>75%概率(80%把握度;假设风险降低50%)。
主要发现
- 胎儿生长或羊水异常检出率干预前7.1% vs 干预后22.2%(P<.0001;诊断所需人数7,95%置信区间5-9)。
- 新生儿复合不良结局干预前568人中15例(2.6%) vs 干预后661人中12例(1.8%)(风险降低概率83%;后验相对风险0.69,95%可信区间0.34-1.42)。
- 母体复合不良结局干预前8.6% vs 干预后6.5%(风险降低概率90%;后验相对风险0.74,95%可信区间0.49-1.15)。
- 减少新生儿复合不良结局的需治疗人数为121(95%置信区间40-200)。
- 减少母体复合不良结局的需治疗人数为46(95%置信区间19-74),预防剖宫产的需治疗人数为18(95%置信区间9-31)。
关键数值与推荐
- 主要结局为新生儿复合不良结局,包括5分钟Apgar评分≤5、脐带pH<7.00、产伤(骨折或臂丛神经麻痹)、插管>24小时、缺氧缺血性脑病、惊厥、败血症(血培养证实菌血症)、胎粪吸入综合征、III或IV级脑室内出血、脑室周围白质软化、坏死性小肠结肠炎、36周后死产或出生后28天内新生儿死亡。
- 母体复合不良结局包括绒毛膜羊膜炎、伤口感染、估计失血量>1000 mL、输血、深静脉血栓或肺栓塞、入住重症监护室或死亡。
临床怎么用
- 在低危妊娠中,可考虑在36.0-37.6周实施普遍性晚孕期超声检查以减轻新生儿和母体复合不良结局(作者结论)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In low-risk pregnancies, a third-trimester ultrasound examination is indicated if fundal height measurement and gestational age discrepancy are observed. Despite potential improvement in the detection of ultrasound abnormality, prior trials to date on universal third-trimester ultrasound examination in low-risk pregnancies, compared with indicated ultrasound examination, have not demonstrated improvement in neonatal or maternal adverse outcomes. OBJECTIVE: The primary objective was to determine if universal third-trimester ultrasound examination in low-risk pregnancies could attenuate composite neonatal adverse outcomes. The secondary objectives were to compare changes in composite maternal adverse outcomes and detection of abnormalities of fetal growth (fetal growth restriction or large for gestational age) or amniotic fluid (oligohydramnios or polyhydramnios). STUDY DESIGN: Our pre-post intervention study at 9 locations included low-risk pregnancies, those without indication for ultrasound examination in the third trimester. Compared with indicated ultrasound in the preimplementation period, in the postimplementation period, all patients were scheduled for ultrasound examination at 36.0-37.6 weeks. In both periods, clinicians intervened on the basis of abnormalities identified. Composite neonatal adverse outcomes included any of: Apgar score ≤5 at 5 minutes, cord pH <7.00, birth trauma (bone fracture or brachial plexus palsy), intubation for >24 hours, hypoxic-ischemic encephalopathy, seizure, sepsis (bacteremia proven with blood culture), meconium aspiration syndrome, intraventricular hemorrhage grade III or IV, periventricular leukomalacia, necrotizing enterocolitis, stillbirth after 36 weeks, or neonatal death within 28 days of birth. Composite maternal adverse outcomes included any of the following: chorioamnionitis, wound infection, estimated blood loss >1000 mL, blood transfusion, deep venous thrombus or pulmonary embolism, admission to intensive care unit, or death. Using Bayesian statistics, we calculated a sample size of 600 individuals in each arm to detect >75% probability of any reduction in primary outcome (80% power; 50% hypothesized risk reduction). RESULTS: During the preintervention phase, 747 individuals were identified during the initial ultrasound examination, and among them, 568 (76.0%) met the inclusion criteria at 36.0-37.6 weeks; during the postintervention period, the corresponding numbers were 770 and 661 (85.8%). The rate of identified abnormalities of fetal growth or amniotic fluid increased from between the pre-post intervention period (7.1% vs 22.2%; P<.0001; number needed to diagnose, 7; 95% confidence interval, 5-9). The primary outcome occurred in 15 of 568 (2.6%) individuals in the preintervention and 12 of 661 (1.8%) in the postintervention group (83% probability of risk reduction; posterior relative risk, 0.69 [95% credible interval, 0.34-1.42]). The composite maternal adverse outcomes occurred in 8.6% in the preintervention and 6.5% in the postintervention group (90% probability of risk; posterior relative risk, 0.74 [95% credible interval, 0.49-1.15]). The number needed to treat to reduce composite neonatal adverse outcomes was 121 (95% confidence interval, 40-200). In addition, the number to reduce composite maternal adverse outcomes was 46 (95% confidence interval, 19-74), whereas the number to prevent cesarean delivery was 18 (95% confidence interval, 9-31). CONCLUSION: Among low-risk pregnancies, compared with routine care with indicated ultrasound examination, implementation of a universal third-trimester ultrasound examination at 36.0-37.6 weeks attenuated composite neonatal and maternal adverse outcomes.
引用
- Roberts AW, Hotra J, Soto E, et al. Indicated vs universal third-trimester ultrasound examination in low-risk pregnancies: a pre-post-intervention study. Am J Obstet Gynecol MFM. 2024. PMID: 38583714. doi:10.1016/j.ajogmf.2024.101373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。